Item 8.01 Other Events.

On August 17, 2022, Blueprint Medicines Corporation issued a press release and hosted an investor call and live webcast to announce the top-line data from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) in patients with non-advanced systemic mastocytosis (SM) demonstrating clinically meaningful and highly significant improvements across the primary and all key secondary endpoints. A copy of the press release and the presentation from the investor call are filed herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.    Description
  99.1           Press release issued by Blueprint Medicines Corporation on August 17,
               2022
  99.2           Presentation by Blueprint Medicines Corporation at investor call on
               August 17, 2022
104            Cover Page Interactive Data File (embedded within the Inline XBRL
               document and incorporated as Exhibit 101)

© Edgar Online, source Glimpses